Anavex Life Sciences (AVXL) is a publicly traded Healthcare sector company. As of November 3, 2026, AVXL trades at $1.15 with a market cap of $110.31M and a P/E ratio of -2.88. AVXL moved -3.78% today. Year to date, AVXL is -68.91%; over the trailing twelve months it is -85.65%. Its 52-week range spans $1.14 to $13.99. Rallies surfaces AVXL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Anavex receives FDA clearance for blarcamesine in Fragile X syndrome: Anavex received FDA clearance for its investigational new drug application for blarcamesine in Fragile X syndrome, opening the U.S. application. A Phase 2a study will evaluate the drug in adult males with the syndrome.
| Metric | Value |
|---|---|
| Price | $1.15 |
| Market Cap | $110.31M |
| P/E Ratio | -2.88 |
| EPS | $-0.54 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.99 |
| 52-Week Low | $1.14 |
| Volume | 1.03M |
| Avg Volume | 0 |
| Revenue (TTM) | $4.68M |
| Net Income | $-46.38M |
| Gross Margin | 0.00% |
AVXL analyst coverage data. Average price target: $0.00.